PDCD1 and hepatocellular carcinoma: The results of phase 1/2 and 2 clinical trials in HCC patients with single use of blocking antibodies of the PD-1 pathway led to approval of these agents by the United States Food and Drug Administration (FDA) for the treatment of HCC [13,14].